Lexicon Pharmaceuticals, Inc. (LXRX)
- Previous Close
1.8400 - Open
1.8500 - Bid 1.7600 x 600
- Ask 1.7900 x 1000
- Day's Range
1.7600 - 1.8500 - 52 Week Range
0.9200 - 3.7300 - Volume
1,847,436 - Avg. Volume
3,904,406 - Market Cap (intraday)
639.841M - Beta (5Y Monthly) 1.38
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8300 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.25
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
www.lexpharma.comRecent News: LXRX
Performance Overview: LXRX
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LXRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LXRX
Valuation Measures
Market Cap
639.84M
Enterprise Value
390.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
180.24
Price/Book (mrq)
2.22
Enterprise Value/Revenue
169.05
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.08%
Return on Equity (ttm)
-102.72%
Revenue (ttm)
2.31M
Net Income Avi to Common (ttm)
-193.58M
Diluted EPS (ttm)
-0.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
355.6M
Total Debt/Equity (mrq)
36.78%
Levered Free Cash Flow (ttm)
-111.15M
Research Analysis: LXRX
Company Insights: LXRX
LXRX does not have Company Insights